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Mechanisms to reduce lameness associated with osteoarthritis (OA) are vital to equine 
health and performance. This study was designed to quantify response to autologous, 
intra-articular platelet-rich plasma (PRP) in horses with OA. Kinetic gait analysis was 
performed on 12 horses with unilateral forelimb lameness and OA in the same limb 
before and after intra-articular anesthesia (IAA). Radiographs and kinetic data were 
obtained before and 6 and 16 weeks after PRP administration to same joint, 4 weeks 
after IAA. Statistical evaluations included filtration effect on platelet concentration, rela-
tionship between kinetic variable changes after IAA versus PRP in the affected limb, and 
associations between response to PRP and response to IAA, platelet concentration, and 
radiographic OA. A positive response to IAA or PRP was defined as ≥5% improvement 
in peak vertical force, vertical impulse, or breaking impulse of the affected limb. Out 
of 10 horses that responded to IAA, 3 responded to PRP at both time points and 4 
responded at one. Of the two horses that did not respond to IAA, one responded to 
PRP at both time points. Filtration increased platelet concentration significantly. The rela-
tionship between kinetic variable alterations of the affected limb after IAA and PRP was 
not significant, and response to PRP was not associated with response to IAA, platelet 
concentration, or radiographic OA. Changes in kinetic variables following IAA in joints 
with naturally occurring OA provide a custom standard to assess intra-articular therapy. 
Kinetic gait changes after intra-articular PRP are variable in horses with moderate to 
severe forelimb OA.
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inTrODUcTiOn
Joint pain from osteoarthritis (OA) accounts for over 60% of equine lameness (1). The economic 
impact of lameness is substantial; annual direct and indirect costs are as high as $1 billion per 
year in the United States horse population of over 9.2 million (2). There is no known cure or gold 
standard treatment for OA. Signs are often managed with various combinations of systemic and local 
TaBle 1 | ground reaction force variables assessed for changes 
following intra-articular anesthesia and platelet-rich plasma therapy.
abbreviation Variable
PVFZ Peak vertical force
IMPZ Vertical impulse
PFB Peak breaking force
PFP Peak propulsion force
IMPB Braking impulse
IMPP Propulsion impulse
ML Mean loading rate
MU Mean unloading rate
Lmax Maximum loading rate
Umax Maximum unloading rate
TaBle 2 | radiographic carpal osteoarthritis (Oa) severity scoring 
system.
radiographic changes Oa score
Intermediate or radial carpal bone corner or chip fragments 3
Osteoarthritis signs 3
Third carpal bone sclerosis 3
Corner or chip fragment and osteoarthritis signs 4
Slab fracture third carpal bone 5
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therapies that include non-steroidal anti-inflammatory drugs, 
chondroprotectants, corticosteroids, homeopathic supplements, 
and blood derivatives (1). Oral and injectable treatments have 
inconsistent results, potential side effects, and do not stop disease 
progression (3, 4).
Over the last few decades, platelet-rich plasma (PRP) has 
become increasingly popular to treat musculoskeletal damage 
and degeneration (5). Platelet growth factors are reported to 
enhance in  vivo articular cartilage regeneration, but clinical 
efficacy is inconsistent (6). Variable response to PRP therapy has 
been attributed to distinct isolation and preparation methods 
that impact platelet concentration and quality, as well as filtrate 
composition (5, 6). Additionally, inconsistent treatment response 
may stem from differences among stages of naturally occurring 
OA that are distinct from each other and artificial models of joint 
trauma (7).
The overarching objective of this study was to evaluate the 
effect of autologous PRP on lameness in a population of horses 
with naturally, occurring forelimb OA. An initial goal was to 
establish a repeatable mechanism to objectively assess gait 
changes in the population by identifying kinetic gait variables that 
improved by a minimum of 5% from baseline within the major-
ity of study subjects that exhibited reduced lameness following 
intra-articular anesthesia (IAA). Hence, the first hypothesis was 
that kinetic variables change in a consistent pattern among horses 
that exhibit reduced lameness following IAA in forelimb joints 
with naturally occurring OA (Table 1) (8, 9). The findings were 
applied to test the second hypothesis that kinetic gait variables 
change in the same magnitude and direction following IAA and 




A protocol (#10-092) was approved by the Louisiana State 
University (LSU) Institutional Animal Care and Use Committee 
prior to study initiation. Horses from the LSU Equine Health 
Studies Program research herd were evaluated for inclusion in 
the study using the following criteria: (1) adult horses of either 
sex, (2) a subjective American Association of Equine Practition-
ers (AAEP) lameness grade of 2 or 3 in a single forelimb, and (3) 
confirmed moderate to severe radiographic OA in the fetlock or 
carpus of the affected forelimb. All horses received a complete 
physical exam, and lameness was subjectively scored by a licensed 
veterinarian according to the AAEP lameness scale (10). Radio-
graphic changes in the carpus or fetlock of the affected limb were 
scored according to published parameters (metacarpophalangeal 
joint) (11) or a custom scoring system (carpometacarpal joint; 
Table 2) by a board certified veterinary radiologist. Horses were 
sedated with 5 mg/kg xylazine IV (Lloyd, Inc., Shenandoah, IA, 
USA) for standard, orthogonal radiographs prior to inclusion as 
well as 6 and 16 weeks after PRP treatment.
study cohorts
A comprehensive kinetic gait analysis was performed on all horses 
(below) to determine the effect of IAA and PRP on 10 gait vari-
ables of each of the four limbs (Table 1). The changes observed 
after IAA served as the study standard for comparing the changes 
following PRP. It was anticipated that subjects that had detectable 
changes in gait variables after IAA would have similar, detectable 
changes in gait variables after PRP therapy (responders). Those 
subjects that did not have changes in gait variables after IAA were 
not expected to have detectable alterations after PRP therapy 
(non-responders) (Figure 1).
Kinetic gait analysis
Kinetic gait data were collected as previously described (12) 
immediately prior to IAA, 20–25 min after IAA, 4 weeks after IAA 
(immediately prior to PRP administration), and 6 and 16 weeks 
after PRP therapy. A 900 mm × 900 mm force platform (Model 
#BP900900, Advanced Mechanical Technology, Inc., Watertown, 
MA, USA) embedded in the center of a 40-m concrete runway 
was used for all trials. The force platform surface is the same color 
and texture as the runway. An experienced handler trotted all 
horses for all trials. A trial was considered successful if a forelimb 
contacted the force platform followed by contact of the ipsilateral 
hind limb at a velocity of 2.00–3.80 m/s. A force of 50 N trig-
gered data acquisition. Trials were not included if the hoof was 
not straight and completely on the platform or was within 5 cm 
of the platform edge (13). A series of five retroflective photocell 
sensors (Mek92-PAD, Joslyn Clark Controls, Inc., Lancaster, SC, 
USA) were used to determine velocity and acceleration in each 
trial. There is little difference in velocity between lame and sound 
horses (14), so horses were allowed to trot at a comfortable pace 
with no specific speed imposed on them for trials (12). However, 
because of the effect of velocity on ground reaction forces (15), 
the trials used for analysis were selected based on vertical force 
FigUre 1 | study design schematic indicating the number of horses that did (+) or did not respond (−) to intra-articular anesthesia (iaa) according 
to changes in the indicated kinetic variables. Based on the same criteria, the number of horses that did (+) or did not (−) respond to intra-articular platelet-rich 
plasma (PRP), 6 or 16 weeks after administration, within each IAA cohort are also shown. Abbreviations: PVFz, peak vertical force; IMPz, vertical impulse; IMPB, 
breaking impulse.
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step cycle graphs (newton per kilogram versus time) that varied 
<5%. All trials were recorded at a rate of 1000 Hz and processed 
with commercially available software (Acquire v7.3, Sharon 
Software Inc., Dewitt, MI, USA). Four to five trials were included 
for the left and right limbs of each horse.
intra-articular anesthesia
Joints were clipped and aseptically prepared with alternating 
70% isopropyl alcohol and 2% chlorhexidine scrubs. Between 5 
and 10 mL of 2% mepivacaine hydrochloride (Pfizer, Inc., New 
York, NY, USA) was administered to each joint. Volumes varied 
based on joint distention. If positive pressure was experienced, 
fluid administration was stopped. In cases of severe joint effusion, 
3–5 mL of joint fluid was removed prior to injection. After the gait 
trial, compressive bandages consisting of a sterile, non-adhesive 
pad, rolled cotton, and adhesive bandage tape were applied over 
the treated joints. Horses were confined to stalls for 2 days prior 
to bandage removal and return to pasture housing. Complete 
physical exams were performed every 12  h while horses were 
confined to stalls.
Platelet-rich Plasma Treatment
Four weeks after IAA, autologous PRP was prepared with a com-
mercially available kit (E-PET, Pall Corporation, Port Washington, 
NY, USA), according to the manufacturer’s instructions using 
solutions provided. Briefly, the filter system was preloaded with 
9 mL of hypotonic capture solution (sterile water). Next, 55 mL 
of blood was aseptically collected from the jugular vein into a 
60-mL syringe containing 5 mL of anticoagulant citrate dextrose 
solution. The blood–anticoagulant mixture was then added to the 
filter system that was, subsequently, gently inverted at least 10 
times to mix the solutions. Using gravity flow, the mixture was 
filtered through the system over about 10 min. Next, 8 mL of a 
hypertonic harvest solution (Purecell™) was flushed through the 
filter into a separate sterile syringe over 2–4 s. The final isolate 
consisted of the filtrate in the proprietary harvest solution. Kit 
solutions were not individually injected into any treated joints.
Complete blood cell counts were performed (ANTECH 
Diagnostics, Irvine, CA, USA) on blood and filtrate aliquots 
(1 mL) collected in ethylenediaminetetraacetic acid coated vacu-
tainer tubes. Immediately after preparation, 5–10 mL of PRP was 
injected into joints identically to IAA administration. Bandages 
were applied to joints and horses housed in stalls for 2 days prior 
to return to pasture. One veterinarian performed all procedures 
and monitored joints and vital parameters every 12 h during the 
stall confinement.
Data reduction
Gait variables included PVFZ, IMPZ, PFB, PFP, IMPB, IMPP, 
ML, MU, Lmax, and Umax (Table  1). All values were normalized 
to subject weight (newton per kilogram). Percent change was 
calculated as [(treatment value  −  baseline value)/baseline 
value] × 100. Baseline values were those collected prior to IAA 
or PRP, and treatment values were those immediately after IAA 
or 6 or 16  weeks after PRP. Responders were defined as those 
with an increase of ≥5% over baseline in PVFZ, IMPZ, or IMPB 
of the affected limb after either treatment (see Results below for 
additional explanation).
statistical analysis
Mean percent change after IAA was determined for all gait vari-
ables of each limb in all horses. Those limb variables with the high-
est prevalence of improvement among subjects that responded 
to IAA were identified. Changes in platelet concentration after 
FigUre 2 | radiographic Oa scores (mean ± sD) for responders and 
non-responders (a) to iaa and (B) PrP (6 and 16 weeks).
TaBle 3 | radiographic osteoarthritis (Oa) score, platelet-rich plasma (PrP) platelet and white blood cell (WBc) concentrations, and response to  
intra-articular anesthesia (iaa) and PrP of study horses.








Tb 6 432 4 8.97 × 105 1.16 × 104 Yes Yes Yes
Tb 4 496 4 7.23 × 105 1.28 × 104 Yes Yes Yes
Tb 3 472 3 5.20 × 104 3.20 × 103 Yes No No
Paint 15 536 3 2.50 × 105 2.90 × 103 Yes No No
Tb 6 579 4 7.98 × 105 1.31 × 104 Yes No Yes
Tb 9 476 4 6.63 × 105 1.51 × 104 Yes Yes No
Tb 10 572 4 6.21 × 105 1.21 × 104 Yes No No
Tb 4 550 3 9.54 × 105 9.07 × 103 Yes No Yes
Tb 7 480 4 7.20 × 105 1.36 × 104 No No No
Tb 7 551 3 2.69 × 105 6.98 × 103 Yes Yes Yes
Tb 9 523 4 7.02 × 105 1.35 × 104 No Yes Yes
Tb 10 592 5 7.85 × 105 1.40 × 104 Yes Yes No
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filtration were evaluated with Student’s paired t-tests. Unpaired 
t-tests were used to compare OA scores between horses that did 
or did not respond to IAA and PRP. Associations between PRP 
response and IAA response, platelet concentration, and OA sever-
ity were determined with odds ratio tests. Relationships between 
kinetic variable changes after IAA versus PRP at each time point 
were evaluated with Pearson or Spearman’s rank order correla-
tion tests based on the D’Agostino–Pearson omnibus normality 
test. All analyses were performed using commercially available 
software (SAS v9.4, Statistical Analysis Services, Cary, NC, USA; 
GraphPad Prism v6, GraphPad Software, Inc., La Jolla, CA, USA), 
and significance was considered at P < 0.05.
resUlTs
study subjects
Seven geldings and five mares were included in the study 
[521.7 ± 50.1 kg; 7.5 ± 3.3 years (mean ± SD)] (Table 3). Breeds 
included 11 Thoroughbreds and 1 American Paint. There was 
no evidence of systemic or local inflammation associated with 
intra-articular injections based on physical examinations during 
stall confinement and daily assessments during pasture housing.
radiographic Oa
All horses had moderate to severe radiographic OA, and score did 
not change in any horse over the course of the study (Table 2). OA 
scores were not significantly different between IAA (Figure 2A) 
and PRP (Figure 2B) responders versus non-responders. The OA 
severity and response to PEP were not significantly associated.
Kinetic gait analysis
Ground reaction force variables for each of the four limbs did 
not change in a detectable pattern among horses that showed 
reduced lameness after IAA (8, 9); however, increases in PVFZ, 
IMPZ, and IMPB of ≥5% of the affected limb were most preva-
lent. For purposes of this study, a positive response to IAA or 
PRP was defined as ≥5% increase in one or more of the variables 
(PVFZ, IMPZ, or IMPB) of the affected limb. The relationships 
between gait variable changes of the affected limb after IAA and 
PRP were not significant 6 or 16 weeks after PRP treatment.
intra-articular anesthesia
Using the definition of a positive response above, 10/12 horses 
responded to IAA (Figure 3).
Platelet-rich Plasma Treatment
Within those horses that responded positively to IAA (n  = 10), 
three responded positively to PRP 6 and 16  weeks after 
FigUre 3 | Percent change (mean ± sD) in PVFZ, iMPZ, and iMPB of 
the affected limb for (a) horses that responded to iaa and (B) horses 
that did not respond to iaa.
FigUre 4 | Percent change (mean ± sD) in PVFZ, iMPZ, and iMPB of the affected limb for horses that responded to iaa and (a) PrP after 6 weeks, 
(B) PrP after 16 weeks, (c) did not respond to PrP after 6 weeks, and (D) did not respond to PrP after 16 weeks.
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administration, and four responded at one time point only, either 6 
or 16 weeks (Figure 4). Of the horses that did not respond to IAA, 
one responded to PRP treatment at both time points (Figure 5). 
The association between response to IAA and response to PRP 
was not significant.
effect of Platelet concentration
Post-filtration platelet concentration ranged from 5.2 ×  104 to 
9.5 × 105 platelets/μL, a 1.3- to 9.1-fold increase. Mean platelet 
concentration was significantly higher after filtration (Figure 6A; 
P < 0.0001). Platelet concentrations were not significantly differ-
ent between horses that had a positive response to PRP versus 
those that did not respond at either time point (Figure 6B). There 
was no significant association between platelet concentration and 
response to PRP.
DiscUssiOn
The comprehensive gait analysis performed before and after IAA 
in this investigation established a baseline to assess response to 
PRP in a population of horses with naturally occurring, forelimb 
OA. Given the inherent variability among horses with a naturally 
occurring condition, we sought to identify a reproducible mecha-
nism and a standard to compare response to intra-articular therapy 
based on current understanding of gait modifications associated 
with progressive, degenerative joint disease. Subjective lameness 
evaluations are limited by inter- and intra-observer error (10, 16), 
and there is evidence of overestimation of changes in lameness 
FigUre 5 | Percent change (mean ± sD) in PVFZ, iMPZ, and iMPB of the affected limb for horses that did not respond to iaa and (a) responded to 
PrP after 6 weeks, (B) responded to PrP after 16 weeks, (c) did not respond to PrP after 6 weeks, and (D) did not respond to PrP after 16 weeks.
FigUre 6 | Platelet concentration (mean ± sD) (a) prior to and after 
filtration and (B) administered to horses that responded (responders) 
or did not respond (non-responders) to intra-articular PrP 6 or 
16 weeks after administration. Columns with different symbols within 
graphs are significantly different from each other (P < 0.05).
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after treatment (17). Kinetic gait analysis is an established mecha-
nism to overcome many of the limitations (14). Analgesia from 
IAA used for comparison in this study was not necessarily an 
achievable standard for intra-articular therapy since the pain 
relief 6 and 16 weeks after administration is unlikely to reach that 
of complete tissue desensitization. As an additional comparison, 
true negative controls, or horses that did not respond to joint 
desensitization and would therefore be unlikely to respond to 
joint pain relief associated with PRP, were included in the study. 
Based on objective gait analysis of horses with forelimb OA that 
did and did not respond to IAA, response to intra-articular PRP 
varied among horses with naturally occurring, forelimb OA.
Quantification of kinetic gait changes in multiple limbs makes 
it possible to detect compensatory gait changes (9). Evidence sup-
ports that it is necessary to quantify numerous gait variables to 
assess complex kinetic gait alterations (2). These considerations 
were the rationale to evaluate multiple ground reaction force 
variables in all limbs. However, the horses in this study did 
not respond to IAA with a consistent pattern of gait changes as 
expected from responses of horses with pain in only one limb. 
This is not surprising given the age of the population and the 
presence of significant OA in a forelimb joint. While horses were 
subjectively lame in one forelimb, it is likely that they experienced 
other sources of discomfort. As such, the limb and gait variables 
that consistently reflected improved gait in the population were 
selected to compare gait alterations following PRP. Although peak 
7Mirza et al. Equine Intra-articular Platelet Therapy
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breaking force and braking impulse are less commonly used to 
quantify equine lameness, they correlate well to lameness severity 
(2) and superficial digital flexor tendonitis pain (18).
The equine population used in this study had joint changes 
that were likely beyond those typically considered consistent with 
continued use. Several available studies support that PRP treat-
ment appears to be more effective in younger patients, human 
and equine, with mild cases of OA (19, 20). The population in 
this study was selected with the goal to ensure consistent forelimb 
lameness across trials to reduce potential variability or alternat-
ing lameness that could obscure the ability to discern treatment 
response. There are many horses with comparable OA that are 
“pasture sound” or appropriate for light work. These horses could 
benefit from a long-lasting, intra-articular therapy to reduce pain 
associated with OA. Hence, while the population was not consist-
ent with high-performance horses, they represent a significant 
patient population.
Joint changes associated with iatrogenic injury are often used 
to evaluate therapeutic efficacy of autologous products (21). Such 
models are more closely representative of acute, traumatic OA 
in an otherwise healthy joint environment (7). The majority 
of clinical cases are progressive OA (1), a scenario that is best 
replicated through naturally occurring disease (22). Additionally, 
gait is often assessed with one kinetic gait variable in a single limb 
or via subjective evaluation (19, 23). These distinctions, among 
others, could account for the differences in results among stud-
ies. Additionally, a challenge of naturally occurring OA is that 
cartilage damage and joint environments can vary widely among 
joints with comparable radiographic changes (24, 25). Synovial 
fluid analysis may have provided additional information about 
joint inflammation; however, direct observation is required to 
assess differences in degenerative joint changes (26). Hence, vari-
able responses among horses with seemingly similar radiographic 
OA may be attributable to significant differences in the local joint 
environment.
The duration of autologous platelet treatments is variable. 
Some reports indicate that treatment effectively reduces lame-
ness in horses up to 8  months (23). Others suggest a decline 
in efficacy between 12 and 52  weeks after therapy, with most 
significant improvement between 7 and 14 days (19). Likely, the 
duration of response is directly related to the joint condition, 
including articular and periarticular tissue changes. As such, it 
is possible that the peak effect of the treatment was not captured 
at the 6- and 16-week time points in this study. The initial 
assessment point was selected to replicate reasonable therapeutic 
expectations in that more frequent injections, within 6  weeks, 
may not be physically reasonable or financial feasible. The highly 
inflamed joint environment, consistent with advanced OA, may 
shorten the effect of PRP, so earlier assessment points may have 
made it possible to identify a response that was not detected in 
this study. The 16-week time point was included to evaluate the 
duration of detectable effects in individual animals to help guide 
treatment strategies. More frequent assessments over the course 
of the study might have made it possible to determine a window 
during which treatment was effective for a greater number of 
horses.
A potential advantage of the system evaluated in this study 
is the fact that PRP can be isolated without the need for cen-
trifugation, making “stall side” PRP preparation possible. Overall 
platelet concentrations were significantly higher after filtration, 
but numbers varied among preparations. There is no therapeutic 
standard for platelet concentration in PRP preparations (5). A 
proposed target concentration is around 1 × 106 platelets/μL or 
a threefold to fivefold increase over whole blood, though studies 
have shown successful treatments with both higher and lower 
concentrations (27, 28). The potential effect of the white blood 
cell (WBC) concentration on PRP benefits is also a contemporary 
question with no clear answer. At present, a maximum concentra-
tion of 3 × 103 WBC/μL is thought to avoid inflammatory cytokine 
accumulation (5). The majority of platelet concentrations in this 
study was consistent with current standards and reports using 
the same filtration kit (29), and there was no detectable effect of 
platelet concentration on treatment response.
Use of platelet products in combination with cell isolates has 
been tested both in  vitro (30) and in  vivo (31). Platelet lysate 
reportedly increases proliferation of equine adult multipotent 
stromal cells (MSCs) from adipose tissue in vitro (30), potentially 
due to high concentrations of growth factors (32). However, at 
high concentrations, platelet lysate decreases equine cord blood 
MSC proliferation in  vitro (33). An investigation to evaluate 
the impact of autologous platelet-enriched fibrin scaffold with 
or without bone marrow-derived multipotent stromal cells 
(BMSCs) on equine stifle cartilage repair did not show a benefit 
of BMSCs (31). Another showed improved healing and lower 
inflammatory infiltrate in experimental equine tendon lesions 
treated with adipose-derived MSCs in platelet concentrate versus 
phosphate-buffered saline alone (34). The information highlights 
ongoing efforts to test and institute novel treatment options using 
progenitor cells and platelets to augment the efficacy of either 
alone.
This comprehensive evaluation of autologous PRP therapy 
in a population of horses with naturally occurring, forelimb OA 
provides unique information owing to the study design. Horses 
selected for inclusion based on specific criteria were treated, 
assessed, and housed under identical conditions throughout 
the study period. Additionally, gait changes were evaluated 
with quantifiable, kinetic measures. Potential kinetic changes 
were compared not only to a pretreatment baseline but also to a 
“gold standard” of joint anesthesia for each horse. Finally, horses 
that did and did not show kinetic gait changes associated with 
joint anesthesia were treated with PRP to test the potential for 
improvement unrelated to pain reduction in the treated joint. 
Based on the study findings, the first hypothesis is rejected. 
Kinetic gait variables did not change consistently in horses with 
forelimb OA following IAA. Nonetheless, meaningful kinetic 
variables for individual assessment of gait changes 6 and 16 weeks 
after PRP administration were identified for the study popula-
tion. Similarly, the second hypothesis is rejected since kinetic 
gait variables changed in the same magnitude and direction in 
less than half of the horses after IAA and PRP administration. 
The outcomes suggest that there may be a potential benefit of 
autologous, intra-articular PRP therapy for forelimb OA in some 
8Mirza et al. Equine Intra-articular Platelet Therapy
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horses. Additional work, including double-blind, randomized 
studies with large numbers of participants and more frequent 
observations over longer durations, is required to determine 
specific characteristics of degenerative joint disease that may 
influence the clinical effects.
cOnclUsiOn
Together, the results of this study indicate variable changes in 
kinetic gait parameters following intra-articular administration of 
autologous PRP in horses with naturally occurring, forelimb OA.
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